Literature DB >> 27294569

Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia.

Lingmin Song1, Wenhao Shen, Heng Zhang, Qiwu Wang, Yongquan Wang, Zhansong Zhou.   

Abstract

This study aimed to identify the differential expression levels of androgen receptor (AR), estrogen receptors (ERα, ERβ), and progesterone receptor (PGR) between normal prostate and benign prostatic hyperplasia (BPH). The combination of immunohistochemistry, quantitative real-time reverse transcription polymerase chain reaction, and Western blotting assay was used to identify the distribution and differential expression of these receptors at the immunoactive biomarker, transcriptional, and protein levels between 5 normal human prostate tissues and 40 BPH tissues. The results were then validated in a rat model of BPH induced by testosterone propionate and estradiol benzoate. In both human and rat prostate tissues, AR was localized mainly to epithelial and stromal cell nuclei; ERα was distributed mainly to stromal cells, but not exclusively; ERβ was interspersed in the basal layer of epithelium, but sporadically in epithelial and stromal cells; PGR was expressed abundantly in cytoplasm of epithelial and stromal cells. There were decreased expression of ERα and increased expression of PGR, but no difference in the expression of ERβ in the BPH compared to the normal prostate of both human and rat. Increased expression of AR in the BPH compared to the normal prostate of human was observed, however, the expression of AR in the rat prostate tissue was decreased. This study identified the activation of AR and PGR and repression of ERα in BPH, which indicate a promoting role of AR and PGR and an inhibitory role of ERα in the pathogenesis of BPH.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27294569      PMCID: PMC4978112          DOI: 10.17305/bjbms.2016.1209

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  27 in total

1.  Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men.

Authors:  A C Hetzl; W J Fávaro; A Billis; U Ferreira; V H A Cagnon
Journal:  Microsc Res Tech       Date:  2012-05-31       Impact factor: 2.769

Review 2.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

Review 3.  Monitoring androgen replacement therapy: testosterone and prostate safety.

Authors:  A Morales
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

4.  Gene expression profiles in human BPH: utilization of laser-capture microdissection and quantitative real-time PCR.

Authors:  K Suzuki; H Matsui; M Hasumi; Y Ono; H Nakazato; H Koike; K Ito; Y Fukabori; K Kurokawa; H Yamanaka
Journal:  Anticancer Res       Date:  2001 Nov-Dec       Impact factor: 2.480

Review 5.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

6.  Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Authors:  Tristan M Nicholson; Priyanka D Sehgal; Sally A Drew; Wei Huang; William A Ricke
Journal:  Differentiation       Date:  2013-06-20       Impact factor: 3.880

Review 7.  Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.

Authors:  Tim M van der Sluis; André N Vis; R Jeroen A van Moorselaar; Hong N Bui; Marinus A Blankenstein; Eric J H Meuleman; Annemieke C Heijboer
Journal:  BJU Int       Date:  2011-10-12       Impact factor: 5.588

8.  Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone.

Authors:  B G Mobbs; I E Johnson; E R DeSombre; J Toth; A Hughes
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

9.  Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control.

Authors:  Yue Yu; Liangliang Liu; Ning Xie; Hui Xue; Ladan Fazli; Ralph Buttyan; Yuzhuo Wang; Martin Gleave; Xuesen Dong
Journal:  J Clin Endocrinol Metab       Date:  2013-05-10       Impact factor: 5.958

Review 10.  Androgen receptor roles in the development of benign prostate hyperplasia.

Authors:  Kouji Izumi; Atsushi Mizokami; Wen-Jye Lin; Kuo-Pao Lai; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-04-06       Impact factor: 4.307

View more
  8 in total

1.  Short-term exposure to chrysin promotes proliferative responses in the ventral male prostate and female prostate of adult gerbils.

Authors:  Mônica S Campos; João P A Silva; Danilo S Lima; Luis O Regasini; Mara Rúbia Marques; Manoel F Biancardi; Sebastião R Taboga; Fernanda C A Santos
Journal:  Int J Exp Pathol       Date:  2019-05-26       Impact factor: 1.925

2.  Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene.

Authors:  Kai Wang; Song Jin; Dongdong Fan; Mingshuai Wang; Nianzeng Xing; Yinong Niu
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240

3.  Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression.

Authors:  Thea Grindstad; Elin Richardsen; Sigve Andersen; Kaja Skjefstad; Mehrdad Rakaee Khanehkenari; Tom Donnem; Nora Ness; Yngve Nordby; Roy M Bremnes; Samer Al-Saad; Lill-Tove Busund
Journal:  Sci Rep       Date:  2018-07-27       Impact factor: 4.379

4.  Estrogen regulates the proliferation and inflammatory expression of primary stromal cell in benign prostatic hyperplasia.

Authors:  Bo Chen; Dehong Cao; Zeyu Chen; Yin Huang; Tianhai Lin; Jianzhong Ai; Liangren Liu; Qiang Wei
Journal:  Transl Androl Urol       Date:  2020-04

5.  TILRR (FREM1 isoform 2) is a prognostic biomarker correlated with immune infiltration in breast cancer.

Authors:  Xiao-Yi Xu; Wen-Jing Guo; Shi-Hua Pan; Ying Zhang; Feng-Lin Gao; Jiang-Tao Wang; Sheng Zhang; He-Ying Li; Ren Wang; Xiao Zhang
Journal:  Aging (Albany NY)       Date:  2020-10-08       Impact factor: 5.682

6.  Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.

Authors:  Weiqiang Li; Robert J Klein
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-11-20       Impact factor: 5.554

7.  N-Butanol and Aqueous Fractions of Red Maca Methanolic Extract Exerts Opposite Effects on Androgen and Oestrogens Receptors (Alpha and Beta) in Rats with Testosterone-Induced Benign Prostatic Hyperplasia.

Authors:  Diego Fano; Cinthya Vásquez-Velásquez; Cynthia Gonzales-Castañeda; Emanuel Guajardo-Correa; Pedro A Orihuela; Gustavo F Gonzales
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-11       Impact factor: 2.629

8.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

Authors:  Deli Liu; Jonathan E Shoag; Daniel Poliak; Ramy S Goueli; Vaishali Ravikumar; David Redmond; Aram Vosoughi; Jacqueline Fontugne; Heng Pan; Daniel Lee; Domonique Thomas; Keyan Salari; Zongwei Wang; Alessandro Romanel; Alexis Te; Richard Lee; Bilal Chughtai; Aria F Olumi; Juan Miguel Mosquera; Francesca Demichelis; Olivier Elemento; Mark A Rubin; Andrea Sboner; Christopher E Barbieri
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.